80 related articles for article (PubMed ID: 7799334)
1. Increased type I collagen degradation in early rheumatoid arthritis.
Kotaniemi A; Isomäki H; Hakala M; Risteli L; Risteli J
J Rheumatol; 1994 Sep; 21(9):1593-6. PubMed ID: 7799334
[TBL] [Abstract][Full Text] [Related]
2. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
[TBL] [Abstract][Full Text] [Related]
3. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
[TBL] [Abstract][Full Text] [Related]
4. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease.
Valleala H; Laasonen L; Koivula MK; Mandelin J; Friman C; Risteli J; Konttinen YT
J Rheumatol; 2003 Mar; 30(3):468-73. PubMed ID: 12610803
[TBL] [Abstract][Full Text] [Related]
5. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up.
Paimela L; Leirisalo-Repo M; Risteli L; Hakala M; Helve T; Risteli J
Br J Rheumatol; 1994 Nov; 33(11):1012-6. PubMed ID: 7981987
[TBL] [Abstract][Full Text] [Related]
6. Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study.
Aman S; Paimela L; Leirisalo-Repo M; Risteli J; Kautiainen H; Helve T; Hakala M
Rheumatology (Oxford); 2000 Sep; 39(9):1009-13. PubMed ID: 10986307
[TBL] [Abstract][Full Text] [Related]
7. Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis.
Hakala M; Risteli L; Manelius J; Nieminen P; Risteli J
Ann Rheum Dis; 1993 Dec; 52(12):866-9. PubMed ID: 8311537
[TBL] [Abstract][Full Text] [Related]
8. A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis.
St Clair EW; Moak SA; Wilkinson WE; Sanders L; Lang T; Greenwald RA
J Rheumatol; 1998 Aug; 25(8):1472-9. PubMed ID: 9712086
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
Al-Awadhi A; Olusi S; Al-Zaid N; Prabha K
J Rheumatol; 1999 Jun; 26(6):1250-6. PubMed ID: 10381038
[TBL] [Abstract][Full Text] [Related]
10. Increased type I collagen degradation correlates with disease activity in reactive arthritis.
Kotaniemi A; Risteli J; Aho K; Hakala M
Clin Exp Rheumatol; 2003; 21(1):95-8. PubMed ID: 12673897
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
Knudsen LS; Klarlund M; Skjødt H; Jensen T; Ostergaard M; Jensen KE; Hansen MS; Hetland ML; Nielsen HJ; Johansen JS
J Rheumatol; 2008 Jul; 35(7):1277-87. PubMed ID: 18597410
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
[TBL] [Abstract][Full Text] [Related]
13. Type I collagen degradation does not diminish with RA disease duration.
Hakala M; Aho K; Aman S; Luukkainen R; Kauppi M; Risteli J
Ann Rheum Dis; 2001 Apr; 60(4):420-2. PubMed ID: 11247878
[TBL] [Abstract][Full Text] [Related]
14. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy.
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Racadot A; Boersma A; Delcambre B
Rev Rhum Engl Ed; 1997 Mar; 64(3):153-9. PubMed ID: 9090763
[TBL] [Abstract][Full Text] [Related]
15. Circulating telopeptide type I is a peripheral marker of thyroid hormone action in hyperthyroidism and during levothyroxine suppressive therapy.
Loviselli A; Mastinu R; Rizzolo E; Massa GM; Velluzzi F; Sammartano L; Mela Q; Mariotti S
Thyroid; 1997 Aug; 7(4):561-6. PubMed ID: 9292943
[TBL] [Abstract][Full Text] [Related]
16. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis.
Garnero P; Gineyts E; Christgau S; Finck B; Delmas PD
Arthritis Rheum; 2002 Jan; 46(1):21-30. PubMed ID: 11817593
[TBL] [Abstract][Full Text] [Related]
17. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N; Juillet F; Garnero P
Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
[TBL] [Abstract][Full Text] [Related]
18. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients.
Lin MK; Farewell V; Vadas P; Bookman AA; Keystone EC; Pruzanski W
J Rheumatol; 1996 Jul; 23(7):1162-6. PubMed ID: 8823686
[TBL] [Abstract][Full Text] [Related]
19. The value of synovial fluid analysis in the assessment of knee joint destruction in arthritis in a three year follow up study.
Aman S; Risteli J; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Hakala M
Ann Rheum Dis; 1999 Sep; 58(9):559-62. PubMed ID: 10460189
[TBL] [Abstract][Full Text] [Related]
20. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction.
Skoumal M; Haberhauer G; Kolarz G; Hawa G; Woloszczuk W; Klingler A
Arthritis Res Ther; 2005; 7(1):R65-70. PubMed ID: 15642144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
